JA
Jesal Agarwal
About Jesal Agarwal
Data last updated:
Jesal Agarwal is a Director at Aurigene Pharmaceutical Services Limited (since 2024), Nominee Director at Dres Energy Private Limited (since 2024) and Additional Director at Dr. Reddy's Bio-Sciences Limited (since 2025), and holds 1 more current directorship. The companies operate in Pharma, Environment and Chemicals and Materials. The 4 current companies with reported revenue have a combined latest revenue of ₹660 Cr; the largest is Aurigene Pharmaceutical Services Limited at ₹645 Cr (FY 2025). Earlier, Jesal Agarwal was an Alternate Director at Medtronic Engineering And Innovation Center Private Limited (2014–2016).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 29 Mar 2024 | 2019 | ₹645 Cr (FY 2025) | Active | |
| Nominee Director | 12 Jun 2024 | 2015 | ₹14.09 Cr (FY 2025) | Active | |
| Additional Director | 24 Nov 2025 | 2000 | ₹1.20 Cr (FY 2025) | Active | |
| Ceo | 04 Jul 2025 | 2021 | ₹5.3 Lakh (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Alternate Director | 29 Sep 2014 | 2011 | ₹667 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Jesal Agarwal
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jesal Agarwal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jesal Agarwal
Jesal Agarwal currently holds 4 directorships: Aurigene Pharmaceutical Services Limited (Director, since 29 Mar 2024, revenue ₹645 Cr (FY 2025)); Dres Energy Private Limited (Nominee Director, since 12 Jun 2024, revenue ₹14.09 Cr (FY 2025)); Dr. Reddy's Bio-Sciences Limited (Additional Director, since 24 Nov 2025, revenue ₹1.20 Cr (FY 2025)); Dr. Reddy's Formulations Limited (Ceo, since 04 Jul 2025, revenue ₹5.3 Lakh (FY 2025)).
Jesal Agarwal was first appointed on 29 Sep 2014 as Alternate Director at Medtronic Engineering And Innovation Center Private Limited. The most recent appointment on record is 24 Nov 2025 at Dr. Reddy's Bio-Sciences Limited.
The 4 current companies of Jesal Agarwal that report revenue have a combined latest revenue of ₹660 Cr: Aurigene Pharmaceutical Services Limited ₹645 Cr (FY 2025); Dres Energy Private Limited ₹14.09 Cr (FY 2025); Dr. Reddy's Bio-Sciences Limited ₹1.20 Cr (FY 2025); Dr. Reddy's Formulations Limited ₹5.3 Lakh (FY 2025).
Jesal Agarwal held 1 earlier board appointment: Medtronic Engineering And Innovation Center Private Limited (Alternate Director, 29 Sep 2014 to 31 Mar 2016).
The current boards of Jesal Agarwal's companies include Akhil Ravi (Aurigene Pharmaceutical Services Limited), Atul Sachdeva (Aurigene Pharmaceutical Services Limited), Deepak Sapra (Aurigene Pharmaceutical Services Limited), Erez Israeli (Aurigene Pharmaceutical Services Limited), Mannam Venkata Narasimham (Aurigene Pharmaceutical Services Limited), Sapna (Aurigene Pharmaceutical Services Limited), among others.